Inozyme's Q4 2024 results reflect its strategic prioritization of the ENPP1 Deficiency program, including a 25% workforce reduction to extend its cash runway into 2026. The company reported a net loss of $102.0 million for the year, with no revenue recorded. Cash and cash equivalents stood at $113.1 million as of December 31, 2024, providing operational stability despite increased R&D expenses. Enrollment for the pivotal ENERGY 3 trial was completed, with topline data expected in Q1 2026.

Inozyme Pharma reported a net loss of $24.6 million for Q3 2024, with cash, cash equivalents, and short-term investments expected to fund operations into the fourth quarter of 2025. The company is advancing INZ-701 across its clinical programs and plans to initiate registrational trials in calciphylaxis and ABCC6 Deficiency in 2025, subject to regulatory alignment and sufficient funding.

Inozyme Pharma reported a net loss of $27.0 million for Q2 2024. The company's cash, cash equivalents, and short-term investments were $144.5 million as of June 30, 2024, which are expected to fund operations into Q4 2025. The company is advancing INZ-701 through clinical programs with several milestones expected by year-end.

Inozyme Pharma reported a net loss of $23.3 million, or $0.38 loss per share, for the quarter ended March 31, 2024. The company's cash, cash equivalents, and short-term investments were $166.2 million as of March 31, 2024, which are expected to fund operations into the fourth quarter of 2025.

Inozyme Pharma reported a net loss of $71.2 million for the year ended December 31, 2023. The company's cash, cash equivalents, and short-term investments were $188.6 million as of December 31, 2023, expected to fund operations into the fourth quarter of 2025. Topline data from ongoing Phase 1/2 trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency are expected in early April.

Inozyme Pharma reported a net loss of $15.6 million for the second quarter ended June 30, 2023. The company's cash, cash equivalents, and short-term investments were $140.2 million as of June 30, 2023, which, together with proceeds from July 2023 offering, are expected to fund cash flow requirements into the fourth quarter of 2025.

Inozyme Pharma reported its Q1 2023 financial results, highlighting the advancement of INZ-701 and the anticipation of initiating a pivotal trial for pediatric patients with ENPP1 Deficiency in Q3 2023, pending regulatory approval. The company's cash, cash equivalents, and short-term investments are expected to fund cash flow requirements into the fourth quarter of 2024.

Inozyme Pharma reported its full year 2022 financial results, highlighting upcoming clinical and regulatory milestones remaining on track with previous guidance, and current cash, cash equivalents and short-term investments anticipated to fund cash flow requirements into the fourth quarter of 2024.

Inozyme Pharma reported a net loss of $16.4 million for the third quarter of 2022. The company's cash, cash equivalents, and investments were $141.5 million as of September 30, 2022, which is expected to fund cash flow requirements into the second quarter of 2024.

Inozyme Pharma reported a net loss of $15.3 million, or $0.38 loss per share, for the quarter ended June 30, 2022. The company's cash, cash equivalents, and investments were $151.5 million as of June 30, 2022, which, together with the $25 million available under the first tranche of its debt facility, will enable the Company to fund its cash flow requirements into the second quarter of 2024.

Inozyme Pharma reported a net loss of $16.9 million, or $0.71 loss per share, for the quarter ended March 31, 2022. As of March 31, 2022, cash, cash equivalents, and investments were $97.8 million. The company expects that its existing cash, cash equivalents, and investments, together with the net proceeds of $68.3 million from its April 2022 offering, will be sufficient to fund its operations into the fourth quarter of 2023.

Inozyme Pharma reported its full year 2021 financial results, highlighting the progress of its INZ-701 program and the initiation of its first clinical trial for patients with ENPP1 Deficiency. The company's cash, cash equivalents, and investments were $111.8 million as of December 31, 2021, which is expected to fund operations into the first quarter of 2023.

Inozyme Pharma reported a net loss of $14.3 million for Q3 2021, with cash, cash equivalents, and investments totaling $125.3 million as of September 30, 2021. The company is on track to enroll patients in Phase 1/2 clinical trials in ENPP1 Deficiency and ABCC6 Deficiency in Q4 2021, with preliminary data expected in the first half of 2022.

Inozyme Pharma reported a net loss of $12.5 million for the second quarter ended June 30, 2021. The company's cash, cash equivalents, and investments totaled $137.5 million as of June 30, 2021, which is expected to fund operations into the fourth quarter of 2022.

Inozyme Pharma reported a net loss of $11.1 million for the quarter ended March 31, 2021. The company's cash, cash equivalents, and investments were $147.6 million as of March 31, 2021, which is expected to enable operations into the fourth quarter of 2022.

Inozyme Pharma reported its full year 2020 financial results, highlighting its cash position of $159.9 million, which is expected to fund operations into the second half of 2022. The company is advancing its INZ-701 clinical development program, with Phase 1/2 trials planned for ENPP1 and ABCC6 deficiencies.

Inozyme Pharma reported a net loss of $28.1 million for the third quarter ended September 30, 2020. As of September 30, 2020, cash, cash equivalents and investments were $171.7 million.

Inozyme Pharma reported a net loss of $9.5 million for the second quarter ended June 30, 2020. The company completed an upsized initial public offering in July 2020, raising $128.8 million in gross proceeds. They also submitted an IND for INZ-701 for the treatment of ENPP1 deficiency, which is currently on FDA clinical hold.